WHEN SIMPLE
THINGS BECOME VERYVERYAWFUL

It may be vulvar and vaginal atrophy (VVA), a chronic and progressive medical condition caused by decreased estrogen that affects many menopausal women. VVA is a component of genitourinary syndrome of menopause (GSM) and is characterized by thinning of vaginal tissue and diminishing vaginal blood flow, as well as narrowing and shortening of the vagina.1-5

Scroll for More

VVA HURTS TOO MANY WOMEN

And some of them may be your patients. However, only approximately 50% of menopausal women with VVA discuss VVA symptoms with their healthcare provider (HCP).1

menopausal women
in the United States3
(approximately 1 in 2) menopausal women in the
United States experience VVA symptoms3
(~7%) of menopausal women are
treated with prescription therapy6

Women may spend, on average, more than one-third of their lives in a hypoestrogenic state. 7

CONSIDER JUST HOW PAINFUL VVA CAN BE

VVA can cause a variety of unpleasant symptoms that may not resolve without treatment, including1-5,7-8:

Dyspareunia
Vaginal dryness
Vaginal
and/or vulvar
itching, burning, and soreness
Dysuria/UTIs

Vaginal
bleeding
associated with
sexual activity
Vaginal Infection

THE NUMBERS MAKE A PAINFUL POINT

IN SURVEYS:

44%
44% of menopausal women reported dyspareunia1
55%
55% of menopausal women reported vaginal dryness1
89%
89% of menopausal women with dyspareunia also experienced vaginal dryness9

VVA: A PRICKLY ISSUE FOR BODY, MIND, AND SPIRIT

IN SURVEYS:

59%
of postmenopausal women indicated VVA made them feel “let down” by their bodies despite feeling young inside10
47%
of menopausal women reported that VVA symptoms, including dyspareunia, had a negative impact on their relationship with their partner 1

TOO MANY WOMEN ARE SUFFERING IN SILENCE

Are any of your patients experiencing the Very Very Awful symptoms of VVA? Asking just one more question could change everything.

Menopause, it doesn't have to hurt.
Click below to view ACOG and NAMS position statements

ACOG POSITION STATEMENT NAMS POSITION STATEMENT Additional Data on VVA Impact
Learn about a different treatment option

Thank you for requesting more information from TherapeuticsMD. Your information has been received.

We’re sorry, but there was a problem processing your request. Please try again. If the problem persists, please Contact Us .

TherapeuticsMD, Inc. is an innovative women’s healthcare company exclusively focused on developing and commercializing products for women throughout their life cycles.

Learn more about TherapeuticsMD

References: 1. Kingsberg SA, Wysocki S, Magnus L, Krychman ML. Vulvar and vaginal atrophy in postmenopausal women: findings from the REVIVE (REal Women’s VIews of Treatment Options for Menopausal Vaginal ChangEs) survey. J Sex Med. 2013;10(7):1790-1799. 2. Mac Bride MB, Rhodes DJ, Shuster LT. Vulvovaginal atrophy. Mayo Clin Proc. 2010;85(1):87-94. 3. Wysocki S, Kingsberg S, Krychman M. Management of vaginal atrophy: implications from the REVIVE survey. Clin Med Insights Reprod Health. 2014;8:23-30. 4. Portman DJ, Gass ML; Vulvovaginal Atrophy Terminology Consensus Conference Panel. Genitourinary syndrome of menopause: new terminology for vulvovaginal atrophy from the International Society for the Study of Women’s Sexual Health and the North American Menopause Society. Menopause. 2014;21(10):1063-1068. 5. The North American Menopause Society. Management of symptomatic vulvovaginal atrophy: 2013 position statement of The North American Menopause Society. Menopause. 2013;20(9):888-902. 6. IMS SDI’s Total Patient Tracker; Annual 2016. 7. Chapter 1: overview of menopause. Menopause.org. http://www.menopause.org/docs/2012/cg_a.pdf?sfvrsn. Accessed September 6, 2016. 8. Chen L, Ng M, van der Vlugt MH, et al. Statistical Considerations for the Efficacy Assessment of Clinical Studies of Vulvar and Vaginal Atrophy. Therapeutic Innovation & Regulatory Science. 2010;44(5):581-588. 9. Kingsberg SA, Krychman M, Graham S, Bernick B, Mirkin S. The women's EMPOWER survey: identifying women's perceptions on vulvar and vaginal atrophy and its treatment. J Sex Med. 2017;14(3):413-424. 10. Simon J, Kokot-Kierepa M, Goldstein J, Nappi R. Vaginal health in the United States: results from the Vaginal Health: Insights, Views & Attitudes survey. Menopause. 2013; 20(10):1043-1048.